Informations générales (source: ClinicalTrials.gov)

NCT07085767 En recrutement IDF
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
Interventional
  • Tumeurs du sein
Phase 3
Olema Pharmaceuticals, Inc. (Voir sur ClinicalTrials)
novembre 2025
janvier 2032
19 juillet 2026
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
 Voir le détail

Etablissements

Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données
CLCC INSTITUT GUSTAVE ROUSSY Barbara PISTILLI En recrutement IDF 22/07/2026 18:00:06  Contacter

Critères

Tous


- Adult female or male participants.

- ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to
curative therapy.

- Evaluable disease (measurable disease per RECIST 1.1 or bone-only disease).

- De novo advanced breast cancer or with disease recurrence occurring after 12 months
of completing adjuvant endocrine therapy (with or without CDK4/6 inhibitors)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Adequate hematologic, hepatic, and renal functions.

- Female participants can be pre-, peri- or postmenopausal.

- Male and pre- or peri-menopausal female participants must be willing to take a GnRH
(or LHRH) agonist.

Exclusion Criteria:


- Disease recurrence during adjuvant endocrine therapy

- Currently receiving or previously received systemic anti-cancer therapy for ER+,
HER2- advanced breast cancer.

- Previously received treatment with fulvestrant, elacestrant or an investigational
endocrine therapy in any setting.

- History of allergic reactions to study treatment.

- Any contraindications to letrozole and ribociclib.

- Symptomatic central nervous system metastases, carcinomatous meningitis,
leptomeningeal disease, or a spinal cord compression that require immediate
treatment.